BEAM earnings date and last-quarter result: last quarter miss, P/E -41.62. Updated 2026-07-23.
Beam Therapeutics (BEAM) Research Hub
Beam Therapeutics (BEAM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 23.79 USD (-1.08%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -41.62, market cap 2.75B. This hub links to the full technical, earnings and options research available for BEAM.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.79 USD (-1.08%) |
| 52-week range | 22.67 USD – 38.26 USD |
| Trend regime | Range |
| 14-day RSI | 41.7 (Bearish) |
| Trailing P/E | -41.62 |
| Market cap | 2.75B |
| Dividend yield | 0.00% |
Available research for BEAM
Covered Call on BEAM: how it works, illustrative setup around the real 23.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BEAM: how it works, illustrative setup around the real 23.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BEAM: how it works, illustrative setup around the real 23.79 USD price, max profit/loss, breakeven and when to use it. Educational.
BEAM technical analysis: range, last 23.79 USD, RSI 41.7, 52w range 22.67 USD–38.26 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is BEAM in?
Beam Therapeutics (BEAM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BEAM in an uptrend or downtrend?
As of 2026-10-26, BEAM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BEAM's trailing P/E ratio?
BEAM's trailing P/E is -41.62, with a market cap of 2.75B. See the earnings research page for full valuation detail.